Vectus Biosystems Limited · ASX:VBS
Vectus Biosystems — Investor Presentation (November 2021)
36 slides from Vectus Biosystems's investor presentation, Nov 8, 2021
Slide 1: Vectus Biosystems (ASX:VBS)
For personal use only VECTUS BIOSYSTEMS (ASX:VBS)
Slide 2: Corporate Snapshot
CORPORATE For personal use only SNAPSHOT KEY METRICS BOARD OF DIRECTORS ASX VBS Dr Ronald Shnier Shares on issue 31.87m Non-Executive Director and Chairman Market Capitalisation $52.59m Share Price (8/11/21) $1.65 52-week trading range $0.88 - $2.20 Mr Maurie Stang Non-Executive Director and Deputy
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only 3 FIRST IN CLASS EXCEPTIONAL SUCCESSFUL CAPITAL HIGHLY EXPERIENCED ASSETS ADDRESSING PATENT PORTFOLIO RAISE OF $7 MILLION BOARD AND MAJOR UNMET ENCOMPASSING A COMPLETED IN MANAGEMENT TEAM THERAPEUTIC NEEDS LIBRARY OF > 1,000 NOVEMBER 2020 COMPOUNDS VB0004
Slide 4: A Significant Market
A SIGNIFICANT MARKET For personal use only Fibrosis is the thickening and scarring of connective tissue, usually as a result of injury, and is the pathology which underlies: Fibrosis Reversal, a MAJOR unmet need HEART FAILURE LIVER FAILURE Fibrotic disease (largest single item on US health care (40%
Slide 5: 2022 Catalysts
2022 CATALYSTS For personal use only • Complete Phase 1 of Human Safety Trials • Complete Phase 1B Human Trials VB0004 • Initiate engagement with global pharmaceutical companies • Initiate specific programs to encompass other areas of significant unmet therapeutic needs (e.g. post Covid fibrosis)*ZQ
Slide 6: Path to Clinic – VB0004
PATH TO CLINIC – VB0004 For personal use only Validated Platform Transform- Demonstrated Demonstrated Synthesis Cost of IP Covers Sufficient Phase I Human pD Target Technology ational Efficacy in Safety – IND at Scale Goods Composition Patent Life Safety (Efficacy) Agent Animal toxicology Competitiv
Slide 7: Target Validation
TARGET VALIDATION For personal use only Treatment with VIP reversed cardiac fibrosis in multiple animal models data from one was published in the paper entitled “Vasoactive intestinal peptide reverses existing myocardial fibrosis in the rat” Treatment with VIP was also found to reverse interstitial
Slide 8: Path to Clinic – VB0004
PATH TO CLINIC – VB0004 For personal use only Validated Platform Transform- Demonstrated Demonstrated Synthesis Cost of IP Covers Sufficient Phase I Human pD Target Technology ational Efficacy in Safety – IND at Scale Goods Composition Patent Life Safety (Efficacy) Agent Animal toxicology Competitiv
Slide 9: VB0004 & Systolic Blood Pressure
VB0004 & SYSTOLIC BLOOD For personal use only Left: Decrease in SBP from controls in Middle: Difference in SBP from control Right: Change in SBP from levels at the 18 week old SHR treated with VB0004 for SHR treated with VB0004 at 2,500 commencement of the experiment in at 10, 100, 500, 1,000 and 2,
Slide 10: VB0004 & Cardiac Fibrosis
VB0004 & CARDIAC FIBROSIS For personal use only VB0004 has been shown to: 14-Week Control • Rescue cardiac tissue damaged by fibrosis Fibrous tissue (blue staining) is visible around blood vessels and extending • Repair existing cardiac damage between muscle fibres • i.e. VB0004 is transformational
Slide 11: VB0004 & Kidney Fibrosis
VB0004 & KIDNEY FIBROSIS For personal use only In the kidney VB0004 has been 14-Week Control shown to: Fibrosis (blue) partially surrounds • Reverse renal interstitial fibrosis at all doses some but not all tubukes • Restore normal architecture at all doses (i.e. VB0004 is considered transformationa
Slide 12: VB0004 & Pulmonary Fibrosis
VB0004 & PULMONARY FIBROSIS For personal use only In the lung: • VB0004 reversed fibrosis present 2 weeks after treatment 14-Week Control with bleomycin (an anticancer drug) (i.e. VB0004 also transformational in the lung) 20-Week Control Treatment with VB0004 and VB4-A79 VB4-A79 at 20 weeks VB0004 a
Slide 13: Path to Clinic – VB0004
PATH TO CLINIC – VB0004 For personal use only Validated Platform Transform- Demonstrated Demonstrated Synthesis Cost of IP Covers Sufficient Phase I Human pD Target Technology ational Efficacy in Safety – IND at Scale Goods Composition Patent Life Safety (Efficacy) Agent Animal toxicology Competitiv
Slide 14: Demonstrated Safety
DEMONSTRATED SAFETY For personal use only SAD AND MAD CARDIOVASCULAR RESPIRATORY (2 SPECIES) SAFETY SAFETY • Single Ascending Dose (SAD) to • hERG studies - low arrhythmia • Rat study no adverse events 2,000mg/kg no adverse events potential • 7 day Multiple Ascending Dose • Dog cardiovascular safety
Slide 15: Path to Clinic – VB0004
PATH TO CLINIC – VB0004 For personal use only Validated Platform Transform- Demonstrated Demonstrated Synthesis Cost of IP Covers Sufficient Phase I Human pD Target Technology ational Efficacy in Safety – IND at Scale Goods Composition Patent Life Safety (Efficacy) Agent Animal toxicology Competitiv
Slide 16: Synthesis at Scale & Cost
SYNTHESIS AT SCALE & COST For personal use only FIRST GMP SYNTHESIS BY SECOND GMP SYNTHESEIS GLYCOSYN ASSYCHEM • Yield increased as scale increased • Campaign planned to provide 3 • VB0004 manufactured to 5kg scale validation batches • Cost efficient at 5kg scale < $(US) • Confirm consistency of the
Slide 17: Path to Clinic – VB0004
PATH TO CLINIC – VB0004 For personal use only Validated Platform Transform- Demonstrated Demonstrated Synthesis Cost of IP Covers Sufficient Phase I Human pD Target Technology ational Efficacy in Safety – IND at Scale Goods Composition Patent Life Safety (Efficacy) Agent Animal toxicology Competitiv
Slide 18: Intellectual Property
INTELLECTUAL PROPERTY For personal use only VB0004 PATENT PATENT COVERS LIFE • Compositions of matter • Priority date September 2014 • Methods of use • 13 years (+5 years on licensing) VB0004 PATENT GRANTED IN VB0004 METHOD OF ALL MAJOR JURISDICTIONS SYNTHESIS PATENT AT NATIONAL PHASE ENTRY • USA, E
Slide 19: Path to Clinic – VB0004
PATH TO CLINIC – VB0004 For personal use only Validated Platform Transform- Demonstrated Demonstrated Synthesis Cost of IP Covers Sufficient Phase I Human pD Target Technology ational Efficacy in Safety – IND at Scale Goods Composition Patent Life Safety (Efficacy) Agent Animal toxicology Competitiv
Slide 20: Phase 1 Trial
Syneos Health (Nasdaq SYNH) retained to write Investigator Brochure (IB), For personal use only trial protocol and monitor Phase 1 trial Trial design conventional Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Healthy subjects 14 day MAD PHASE 1 Affected individuals 2 groups 28 days 2
Slide 21: Comparable Transactions
COMPARABLE For personal use only TRANSACTIONS Successful Phase 1/1b would place Vectus at the point where many transactions have been completed 21
Slide 22: Fibrotic Liver Disease VB4-A32
For personal use only Fibrotic Liver Disease VB4-A32 22
Slide 23: Hepatic Cirrhosis (Liver Fibrosis)
HEPATIC CIRRHOSIS (LIVER FIBROSIS) For personal use only CAUSES PREVALENCE CURRENT THERAPIES • Genetic • Varies to >40% of the population in • Vaccination Hep A, Hep B for • Infectious (Hep A, B, C) countries such as India, Cambodia, prevention • Alcohol related Vietnam and China due to endemic • Ab
Slide 24: Potential Therapies
POTENTIAL THERAPIES For personal use only FXR agonists Insulin sensitisers THR β agonist Phase 2 reduced liver fat at 6 months, Phase Phase 2b no effect on liver disease, but Phase 2 decreased ALT, AST and liver fat vs 3 no change in liver fat, decreased fibrosis improved insulin sensitivity. placeb
Slide 25: VB4-A32 & Hepatic Cirrhosis
VB4-A32 & HEPATIC CIRRHOSIS For personal use only VB4-A32 demonstrated ability to: • Reduce peri-portal fibrosis in the liver in a dose dependent manner (right and below) • Improve liver function tests (below right) 20-Week Control A32 20 Weeks 25
Slide 26: Fibrotic Lung Disease VB4-A79
For personal use only Fibrotic Lung Disease VB4-A79 26
Slide 27: Pulmonary Fibrosis
PULMONARY FIBROSIS For personal use only Causes Current therapies • Environmental (e.g. air pollution, diesel particles) Current therapies: • Occupational (e.g. dusts such as silica, coal, asbestos, • Regulatory approval approximately 5 years ago cotton dust) • Slows lung function (FVC and 6MWD) dec
Slide 28: Potential Therapies
POTENTIAL THERAPIES For personal use only Pentraxin 2 analogue Medium Chain Fatty Acid Anti-interleukin Antibodies Analogue (PBI4050) No efficacy Phase 2 showed significant slowing of the decline in FVC and stabilisation of 6MWD at 6 Phase 2 PBI4050, alone or combined with months Nintedanib slowed d
Slide 29: VB4-A79: Blood Pressure
For personal use only VB4-A79: BLOOD PRESSURE Systolic and diastolic blood pressure in 20-week SHR following treatment with bleomycin at 14 weeks and randomisation to control, VB0004 or VB4-A79 at 16 weeks. As previously VB0004 significantly decreases both systolic and diastolic pressure while VB4-A
Slide 30: VB4-A79: Pulmonary Fibrosis
For personal use only VB4-A79: PULMONARY FIBROSIS Pulmonary fibrosis in 16-week controls (two weeks after Bleomycin administration) and at 20 weeks after 4 weeks treatment in VB0004, VB4-A79 and vehicle control rats. VB0004 and VB4-A79 were administered at 500pmol/kg/min in the drinking solution (5%
Slide 31: VB4-A79 Histology
VB4-A79 HISTOLOGY For personal use only Lung sections in bleomycin treated rats after 2 weeks of control drinking solution (left), after 6 weeks of control drinking solution 14-Week Control (centre) and after 2 weeks of control drinking solution followed by 4 weeks treatment with VB4-A79 or VB0004 (
Slide 32: Patent Portfolio
PATENT PORFOLIO For personal use only VIP patents for heart, VB0004 library of approx. VB4-P5 and library of VB0001 and related kidney and aortic fibrosis 70 related compounds related compounds compounds compositions – granted all jurisdictions compositions and methods compositions and methods and u
Slide 33: Covid and Fibrosis
COVID AND FIBROSIS For personal use only Sars-Cov2 + ACE2 → ↑ Ang II Cytokine Storm ↑ Agt ↓ ↓ ARDS ↑Ang II ↓ ↙ Fibrosis ICU + Ventillation ↑TNFα → ↑AT1a ↓ ↓ Fibrosis Fibrosis Ang II = Angiotensin II ARDS = Acute Respiratory Distress Syndrome Agt = Angiotensinogen, the Ang II precursor TNFα= Tumour N
Slide 34: VIP, VB0004 and Post Covid Fibrosis
VIP, VB0004 For personal use only AND POST COVID FIBROSIS > VIP and VB0004 downregulate expression of: Agt (and therefore Ang II) TNFα AT1a > Possible role in treating post Covid Fibrosis 34
Slide 35: Why Alzheimers
WHY ALZHEIMERS For personal use only Accumulation of B-amyloid in the brain causes formation of plaques, which disrupt neuronal connections and cause accumulation of Tau proteins, which are dissociated from microtubules within neurones causing tangle formation, a precursor to neuronal cell death. 35
Slide 36: Contact
For personal use only CONTACT MAURIE STANG Non-Executive Director & Deputy Chairman mauries@regionalhealth.com.au KAREN DUGGAN Executive Director & CEO kduggan@vectusbiosystems.com.au 36
Vectus Biosystems — Investor Presentation (November 2021) on 6ix